News & Updates
Filter by Specialty:
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
20 Jul 2022
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
19 Jul 2022
Chronic hepatitis C tied to cardiovascular events in T2DM
In patients with type 2 diabetes mellitus (T2DM), chronic hepatitis C and fatty liver appear to worsen the risk of cardiovascular events, a recent Taiwan study has found.
Chronic hepatitis C tied to cardiovascular events in T2DM
19 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
